Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1988-12-09
1990-07-03
Lee, Mary C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546205, 546206, 546268, 546193, 546261, 546262, 546263, 546318, 546298, 514336, 514318, 514332, 514335, 514350, A61K 3144, A61K 31445, C07D21174, C07D21140
Patent
active
049391607
ABSTRACT:
Hydropyridine derivatives of the formula ##STR1## in which R.sub.1 represents carboxy, lower alkoxycarbonyl, carbamoyl, N-lower alkylcarbamoyl or N,N-di-lower alkylcarbamoyl, R.sub.2 represents hydrogen, an optionally etherified or acylated hydroxy group or an optionally acylated amino group, and R.sub.3 represents a radical of the formula R- (Ia), R-alk.sub.1 - (Ib) or R'=alk.sub.2 - (Ic) in which R represents a benzocycloalkenyl radical having a total of from 8 to 12 ring carbon atoms which is bonded via a saturated carbon atom and which is unsubstituted or is mono- or poly-substituted in the benzo moiety by hydroxy, lower alkoxy, lower alkanoyloxy, halogen, lower alkyl and/or by trifluoromethyl, and/or substituted in the .alpha.-position by lower alkyl, and R' represents a benzocycloalkylidene radical having a total of from 8 to 12 ring carbon atoms which is unsubstituted or is mono- or poly-substituted in the benzo moiety by hydroxy, lower alkoxy, lower alkanoyloxy, halogen, lower alkyl and/or by trifluoromethyl, and alk.sub.1 represents lower alkylene or lower alkylidene and alk.sub.2 represents lower alkyl-.omega.-ylidene, wherein the dotted line is intended to show that there may be a single bond or especially a double bond, and 3-aminopropionic acid compounds of the formula R.sub.3 --NH--CH.sub.2 CH.sub.2 --R.sub.1 (IVc) in which R.sub.1 and R.sub.3 have the meanings given above, and their pharmaceutically acceptable salts, have nootropic properties and can be used as nootropic active ingredients in medicaments. They are manufactured by methods known per se.
REFERENCES:
patent: 3408391 (1968-10-01), Skorcz
patent: 3513244 (1970-05-01), Gittos et al.
patent: 3534055 (1970-10-01), Gittos et al.
patent: 3622614 (1971-11-01), Jenny
patent: 3629463 (1971-12-01), Gittos et al.
patent: 4238488 (1980-12-01), Howe et al.
patent: 4383999 (1983-05-01), Bondinell et al.
patent: 4410519 (1983-10-01), Seiler et al.
patent: 4446141 (1984-05-01), Nakamizo et al.
patent: 4629727 (1986-12-01), Kozlik et al.
patent: 4647559 (1987-03-01), Kuhla et al.
CA97:109663x, Stuches on the Amine Exchange Reactions in C-Mannich Bases, Kulkarni et al., Irclian Chem. Soc., 1982.
J. Med. Chem., vol. 25, pp. 1358-1363 (1982).
Derwent Abstract 84-196786/32 of European 115 409A (1984).
Derwent Abstract 85-035839/06 of Japanese 59231-052-A.
Derwent Abstract 15622y/09 of Japanese 52007946 (1977).
Derwent Abstract 4286y/08 of S.U. 491615 (1976).
Dictionary of Organic Compounds, 5th Ed. (1982).
Derwent Abstract of French Patent No. 2,319,330 (1975).
Frostl Wolfgang
von Sprecher Georg
Zust Armin
Ciba-Geigy Corporation
Lee Mary C.
Scalzo Catherine S.
Villamizar JoAnn
LandOfFree
Hydropyridine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydropyridine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydropyridine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1891182